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Context: Only about 85% of patients with clinical diagnosis complete androgen insensitivity syn-
drome (CAIS) and less than 30% with partial androgen insensitivity syndrome (PAIS) can be ex-
plained by inactivating mutations in the androgen receptor (AR) gene.
Objective: To clarify this discrepancy by in-vitro determination of AR transcriptional activity in
individuals with disorders of sex development (DSD) and male controls.
Design: Quantification of dihydrotestosterone (DHT)-dependent transcriptional induction of the
AR targetgeneapolipoproteinD (APOD) in culturedgenital fibroblasts (GF) (APOD-assay) andnext
generation sequencing (NGS) of the complete coding - and non-coding AR-locus.
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Setting: University Hospital Endocrine research laboratory
Patients: GF from 169 individuals were studied encompassing control males (N68), molecular
definedDSDother thanAIS (N18),AR-mutation positive AIS (N37) and previously undiagnosed
DSD including patients with clinical suspicion of AIS (N46).
Intervention(s): None.
Main Outcome Measure(s): DHT-dependent APOD-expression in cultured GF and AR-mutation
status in 169 individuals.
Results: The APOD-assay clearly separated control individuals (healthy males and molecular de-
fined DSD patients other than AIS) from genetically proven AIS (cutoff2.3-foldAPOD-induction;
100% sensitivity, 93.3% specificity, p0.0001). Of 46 DSD-individuals with no AR-mutation, 17
(37%) fell below the cutoff indicating disrupted androgen signaling.
Conclusions: AR-mutation positive AIS can be reliably identified by the APOD-assay. Its combina-
tion with NGS of the AR-locus uncovered an AR-mutation negative, new class of androgen resis-
tancewhichwepropose tonameAIS type II. Our data support the existenceof cellular components
outside the AR affecting androgen signaling during sexual differentiation with high clinical
relevance.
Sexual development is a complex process involvingthree crucial steps: development of the gonads in the
embryo, synthesis of sex hormones, and sex hormone ac-
tion. Genetic errors in any of these processes can lead to a
wide range of sexual phenotypes that can be broadly in-
cluded under the umbrella term of disorders of sex devel-
opment (DSD) (1–3). Androgen insensitivity syndrome
(AIS) (OMIM#300068) is a DSD that is classically char-
acterized as a disorder of hormone action due to a reduced
or absent functionality of the androgen receptor (AR) pro-
tein encoded by the AR gene. AIS is often suspected to be
a common cause of DSD in a 46,XY individual and may
either be associated with complete feminization of the ex-
ternal genitalia due to a complete lack of AR transcrip-
tional activity (complete AIS, CAIS) (4), a variable level of
feminization/masculinization due to a partial lack of tran-
scriptional activity (partial AIS, PAIS) or isolated male
infertility (mild AIS, MAIS).
For optimal function, the AR is activated through its
ligands, testosterone and the more potent dihydrotestos-
terone (DHT), following which it translocates into the
nucleus and binds to its target genes whose expression
entails the development ofmale internal and external gen-
italia. This process is tightly regulated through coactiva-
tors and corepressors of the AR (5, 6). Many AR target
genes have been described in prostate cancer-derived cell
lines, however, only a handful have been identified in
healthy male genital tissue (7). Among these, apolipopro-
tein D (APOD) has been reported to exhibit the most sig-
nificant induction uponDHT treatment.APOD is a direct
transcriptional target of the AR (8, 9) and a DHT-depen-
dent secretion of APOD has been observed in prostate
cancer cells (10). APOD belongs to the lipocalin protein
family (11) and is able to carry E-3-methyl-2-hexenoic
acid (E-3M2H), the most abundant axillary odorant in
males, to the skin surface ultimately used for pheromonal
communication (12).
While the clinical diagnosis of CAIS is relatively easy
and can be confirmed by identifying a genetic abnormality
in the AR coding sequence (AR-CDS) in more than 85%
of cases, the clinical diagnosis ofPAIS ismoredifficult and,
in addition, less than 30% of cases that are clinically sus-
pected of PAIS are associated with a mutation in the AR
(13). It is not known whether some of those with 46,XY
DSD may, in fact, have a currently unidentified new class
of androgen insensitivity despite the absence of an AR-
CDS mutation, or whether some, or even all, rather have
normal cellular AR function, thus excluding AIS.
To understand the possible coexistence of androgen
resistance without any genetic evidence of a defect in the
AR, we analyzed a cohort of 169 individuals including
male controls, individualswith genetically provenAIS and
individuals with a clinical suspicion but no molecular
proof of AIS in whom genital fibroblasts were available.
Combining AR-sequencing analysis with a functional as-
say for AR-activity by measuring the DHT-dependent
transcriptional induction of the androgen-regulated
APOD-gene in cultured genital fibroblasts (GF) (APOD-
assay) enabled us to discover a newAR-mutation negative
class of androgen resistance which we propose to name
AIS type II.
Materials and Methods
The study was performed in agreement with the vote of the Eth-
ical Committee of the Medical Faculty of the Christian-Al-
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brechts-University, Kiel, Germany (AZ: D415/11) (File S1). GF
received from collaborating partners were included in this study
according to the recommendations of the local ethical commit-
tees. All GF included in this study were double encrypted and
numbered from 1 to 169.
Sample collection
The GF herein analyzed belonged to four major clinical
groups:
The first group (group 1) was established in collaboration
with local urologists and pediatric surgeons and includes scro-
tum-derived control GF from fertile adult patients with normal
virilization of the external genitalia, who underwent vasectomy
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Figure 1. Next generation sequencing of the AR locus. a) Graphic representation of the AR locus and the regions amplified by the haloplex design
(chrX:66,754,874–66 955 461 (hg19)) (shown in green). Highly repetitive sequences were excluded from the design (shown in brown). For
comparison, repetitive elements present in this locus are shown in black. b) Division of the four patient groups from whom cultured GF were
analyzed. When mutations were found in the AR-CDS of GF from group 4 (clinically suspected androgen resistance), they were reallocated to
group 3 (genetically proven AIS). Therefore, two of the initially 41 samples from group 4 with clinically suspected PAIS and seven of the initially
eight samples with clinically suspected CAIS were reallocated to group 3 resulting in 15 GF samples with genetically proven PAIS and 22 samples
with genetically proven CAIS, respectively c) Distribution of mutations found in the CDS of the AR. Red dots represent nonsense mutations, green
dots missense mutations. Synonymous mutations in the coding region were not considered as CDS mutations. The graph was designed using the
Mutation Mapper software from cBioPortal d) Distribution of not annotated SNPs along the sequenced region (green bars).
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(n 30). We included scrotal biopsies of patients under the age
of 18 who underwent orchidopexy due to maldescended testes
(n  13) with normal external genitalia, ie, no hypospadias. In
addition,we used control foreskin fibroblasts frompatientswho
underwent circumcision due to cultural reasons or phimosis (n
25). Genomic DNA of all male control GF cultures was se-
quenced using our custom haloplex NGS (next generation se-
quencing) including up- and downstream sequences, untrans-
lated regions and the introns (Figure 1a).
The second group consists of GF from previously character-
ized 46,XYDSD individuals with a defined molecular diagnosis
other than AIS (group 2). In particular, these individuals carried
mutations in the steroidogenic factor 1 (SF1) gene (NR5A1) (n
2), the 17-hydroxylase gene (CYP17A1) (n  2), the 17-hy-
droxysteroid-dehydrogenase type III gene (HSD17B3) (n  4)
and the 5-reductase type II (5RDII) gene (SRD5A2) (n 8) in
conjunction with ambiguous or female
external genitalia. Biopsies were taken
from either labioscrotal or foreskin/labia
minora tissue.We addedGF from female
(46,XX) individuals with congenital ad-
renal hyperplasia (CAH) due to 21-hy-
droxylasedeficiency (CYP21A2) (n2).
GenomicDNAderived fromGF cultures
of the second group was sequenced via
the custom haloplex NGS AR-panel.
The third group contains labioscrotal
and foreskin/labia minora-derived GF
with a genetic proof ofAIS, inwhommu-
tations in theAR-CDSwere either found
previously via Sanger sequencing or in
this paper through the haloplex NGS
AR-panel (n 37) (group 3). All GF that
revealed an AR-CDS mutation via the
custom haloplex NGS AR-panel were
validated by Sanger sequencing.
The fourth group was compiled from
a collection of labioscrotal and foreskin/
labia minora-derived GF samples from
46,XY DSD individuals without an es-
tablished molecular diagnosis (group 4).
It includes individuals with apparently
unaffected androgen biosynthesis based
on available hormone data supporting a
clinical suspicion of androgen resistance
(n  46). When available, data on the
external genital appearance, basal and
stimulated testosterone levels (HCG-
test) and measurements on AR-ligand
binding (Bmax and Kd) were collected
(suppl. Table 1 and 2). This group may
also contain individuals with a so far un-
diagnosed form of DSD other than AIS.
All GF of group four were sequenced
through our custom haloplex NGS AR-
panel. If an AR-CDS mutation was de-
tected by NGS, Sanger sequencing was
used for confirmation and the GF were
subsequently reallocated to group 3.
Supplemental Table 3 lists all GF in-
cluded in this study according to their
location of biopsy together with the me-
dian age at biopsy.
Primary culturing of genital skin biopsies, the APOD-assay,
next generation sequencing library preparation and sequencing
and further methods are described in the supplemental material.
Results
Separation of GF into AR coding sequence
mutation positive and negative entities
In the group of male controls (group 1) no mutations
were detected in the CDS and the intron-exon boundaries
of the AR. In group 2 (molecular-defined DSD diagnoses
other thanAIS) therewere alsonoAR-CDSor intron-exon
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Figure 2. DHT-dependent AR induced APOD mRNA expression represented as ratio between
ethanol (EtOH)- and DHT-treated GF. A) Scrotum derived male controls (vasectomy, orchidopexy
(group 1)), labioscrotal derived molecular defined DSDs (other DSD (group 2)), and AR-CDS
mutation positive AIS (CAIS, PAIS (group 3)) B) Depiction of cutoff values between male controls
(vasectomy and orchidopexy) and AR-CDS mutation positive AIS (CAIS and PAIS) of 2.29 (100%
sensitivity, 97,7% specificity, P  .0001) and between the same male controls and molecular
defined DSDs (other DSD) of 2.36 (100% sensitivity, 93,3% specificity, P  .0001) C) Foreskin
derived male controls (circumcision (group 1)), molecular defined DSDs (other DSD (group 2)), as
well as AR-CDS mutation positive AIS (CAIS, PAIS (group 3)). D) Depiction of the cutoff value
between male controls (circumcision) and AR-CDS mutation positive AIS (CAIS and PAIS) of 2.36
(100% sensitivity, 100% specificity, P  .0001). Means and standard deviations are included as
error bars. p-values  0.001 are denoted by three stars, those  0.01 bei two stars. Among the
DSD diagnoses other than AIS, empty squares represent SRD5A2-, horizontally half-filled squares
HSD17B3-, vertically half-filled squares CYP17-, crossed squares CYP21A2- and dotted squares
NR5A1-mutations.
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boundary mutations. In all classical AIS individuals (ge-
netically proven AIS, group 3) previously identified by
Sanger sequencing, mutations in the AR-CDS could be
validated by our custom NGS AR-panel, underlining the
validity of the NGS approach. All those individuals in
group 4 with previously undiagnosed forms of DSD in
whom we identified a mutation in the AR-CDS by NGS
(n  9) were reallocated to group 3. In the remaining GF
samples of group4, includingDSDsampleswhereAISwas
suspected (n  46) neither mutations in the AR-CDS nor
in the intron exon boundaries could be detected. A sche-
matic representation of all four groups is shown in Figure
1b. The distribution of detected AR-CDS mutations
within group 3 is schematically shown in Figure 1c and
their exact position is listed in suppl. Table 4. Eight AR-
CDSmutations are not currently listed in theARmutation
database (14) and, to our knowledge, have not been de-
scribed in the literature. These unreported mutations are
frameshift-mutations (n 5), stop-mutations (n 1) and
missense mutations (n  2) (suppl. Table 4). Outside the
coding region, numerous nonannotated SNPs were found
in all four groups. A distribution of those SNPs is shown
in Figure 1d.
Calculation of a cutoff for the functional
classification of male controls (group 1),
molecular-defined DSD other than AIS (group 2)
and AR-CDS mutation positive AIS individuals
(group 3) using the APOD-assay
We now functionally characterized all 169 sequenced
GF by measuring the DHT-triggered ability of the AR to
induce transcription of its target gene APOD (APOD-as-
say). Male control scrotum-derived GF from group 1 (va-
sectomy, orchidopexy) showed a mean DHT-mediated
APOD induction of 3.5 fold (SD 0.85), defining the nor-
mal range of transcriptional function of the AR in this
group (Figure 2a). Scrotum-derivedGF fromgroup2 (mo-
lecular-defined DSD other than AIS) showed the same de-
gree ofAPODup-regulation, confirming uncompromised
functionality of the AR in these cells (Figure 2a). Only one
orchidopexy-derived control GF cell line from an individ-
ual in group 1 showed an unexpectedly low induction of
APOD. In the lightof the completedataset provided in this
manuscript and since the final steps of testicular descent
are androgen dependent, we retrospectively have to con-
clude that this individual has some degree of androgen
resistance (15). In contrast to groups 1 and 2, APOD in-
duction was significantly lower in scrotum-derived GF
from classical AIS individuals (group 3) (P .001). CAIS-
derived GF showed on average no induction (0.96) while
PAIS-derived GF demonstrated an average induction of
1.62 (Figure 2a). This confirms androgen resistance at the
functional molecular level in these cells and underlines the
validity of the APOD-assay.We now calculated the cutoff
between scrotal-derived control GF from group 1 (adults
and children together) and corresponding labioscrotal-de-
rived GF from AIS individuals in group 3 (CAIS and PAIS
together). Consequently, anAPOD induction below 2.28
represents a form of androgen resistance with a sensitivity
of 100% and a specificity of 97.67%, and indicates that
the two groups are separable with high confidence (Figure
2a and b).
From the clinical perspective, it is of much greater rel-
evance to distinguish AIS from other forms of DSD rather
than from clinically unsuspicious male controls. We cal-
culated a cutoff between labioscrotal-derived GF from
group 2 (molecular-defined DSD other than AIS) and
group 3 (AR-CDS mutation positive AIS) of 2.36-fold
APOD induction. Hence, a DHT-mediated APOD induc-
tion under 2.35 distinguishes genetically proven AIS from
other molecular-defined DSDs with a sensitivity of 100%
and a specificity of 93.33% (Figure 2a and b).
A
B
Figure 3. DHT-dependent AR-induced APOD induction in response to
different DHT concentrations in the culture media. a) GF-11, GF-16
and GF-35 are scrotum-derived male control GF (suppl. Table 1). GF
derived from a CAIS patient carrying the p.Ser310fs mutation served as
negative control. The p.Val867Met mutation is shown in black. b) GF-
120, GF-123 and GF-124 are foreskin derived male control GF (suppl.
Table 2). GF derived from a CAIS patient carrying the p.Ser220fs
mutation served as negative control. The p.Tyr782Asp mutation is
shown in black.
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When analyzing foreskin/labia minora-derived GF, the
APOD-assay could again reliably separate male control
fibroblasts (group 1) and GF from AIS individuals har-
boring anAR-CDSmutation (group 3) (Figure 2c). A cut-
off of 2.36-foldAPOD inductionwasdetermined for fore-
skin/labia minora-derived tissue with 100% sensitivity
and specificity (Figure 2c and d). The average DHT-me-
diated APOD induction in CAIS was 0.97 ( no APOD
induction) and 1.92 in PAIS (Figure 2b). Although GF
from individuals of group 2 showed an as high APOD
induction asmale controls (group 1) (Figure 2c), no cutoff
could be calculated as there were not enough correspond-
ing foreskin-derived GF strains available in our DSD-GF-
biobank. When testing two GF strains derived from CAH
individuals carrying CYP21A2 mutations and having a
46,XXkaryotype theirAPOD response toDHTwas com-
parable to that of male controls, confirming that the AR
can be activated byDHT inGF independently of the chro-
mosomal sex (Figure 2a and c).
We than examined whether GF derived from geneti-
cally proven CAIS and PAIS individuals within group 3
could be distinguished from each other by the APOD-
assay. When comparing DHT-mediated APOD induc-
tion, we found a significant difference between PAIS and
CAIS in both labioscrotal and labia minora/foreskin-de-
rived tissues (P .01). However, there was some overlap
due to a fewGF cultures (Figure 2a and c).OneGF cell line
carrying a p.Val867Met mutation in the ligand binding
domain of the AR derived from a CAIS individual still
showed residualAPOD induction. Interestingly,whenus-
ing lower DHT concentrations, APOD induction was
abolished (Figure 3a). Labia minora-derived GF from an-
other CAIS individual bearing the mutation p.Tyr782Asp
again located in the AR-ligand binding domain also
showed residual APOD induction.
However, this partial activity was
even present at lower DHT concen-
trations (Figure 3b). A third GF cell
line was derived from an individual
with predominantly female external
genitalia, and therefore PAIS, carry-
ing a p.Leu174stop mosaic. The lat-
ter was present in 94% of the cul-
tured GF according to the NGS
reads, which is most likely the cause
for complete abolishment of DHT-
mediated APOD induction in spite
of the PAIS phenotype.
We also compared APOD induc-
tionbetweenGFharboring nonsense
ormissensemutations in theARpro-
tein. Nonsense mutations (stop- or
frame shift mutations) never showed
any APOD induction and always belonged to the CAIS
group (apart from the p.Leu174stop mosaic), while mis-
sensemutations had a variableAPOD induction andwere
present in both PAIS and CAIS-derived GF (see suppl.
Table 1 and 2).
In conclusion, the APOD-assay does distinguish CAIS
patients from PAIS individuals, albeit with slightly lower
sensitivity (88.2%) and specificity (90%) (suppl. Figure
8c).
AR-activity in AR-CDS mutation negative GF from
individuals with suspected diagnosis of AIS (group
4)
We then analyzed the large group ofAR-CDSmutation
negative GF derived from individuals with no previously
established DSD diagnosis (group 4) using the APOD-
assay and applied the above calculated cutoffs. Looking at
labioscrotal-derived GF, 24% (n  8) of fibroblast cul-
tures from group 4 fell below the cutoff of 2.28 and there-
fore have to be defined as functionally androgen resistant
(Figure 4a, suppl. Table 1). One of the GF cultures was
from an individual with the suspected clinical diagnosis of
CAIS and showed strongly reduced APOD induction. In
contrast, the remaining 76%(n25)GF cell lines showed
an APOD induction above the cutoff and had an AR-
activity comparable to that of control groups 1 and 2 (Fig-
ure 4a). Therefore, theseGF cell lines have to be defined as
normally androgen responsive. Analyzing the foreskin/la-
biaminora-derivedGF in group 4, themajority (69%, n
9) fell below the cutoff of 2.35. Again, these cultures have
to be defined as androgen insensitive on a functional basis
(Figure 4b, suppl. Table 2). The remaining 31% of fore-
skin/labia minora GF cultures (n  4) behaved like male
A B
Figure 4. DHT-dependent AR-induced APOD induction in AR-CDS negative individuals with
clinically suspected androgen resistance (group 4) derived from a) scrotum/labia majora GF b)
foreskin/labia minora. Suspected androgen resistant GF of group 4 are divided into minimal
androgen resistance (MAIS, micropenis), partial androgen resistance (PAIS, ambiguous external
genitalia) and complete androgen resistance (CAIS, completely female external genitalia).
Included are means and standard deviations. For comparison, the tissue specific controls and AR-
CDS mutation positive GF are shown as well. The calculated cutoffs are drawn as dotted lines.
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foreskin controls (group 1) in terms of APOD induction
and hence androgen insensitivity can be ruled out. In sum-
mary, 17 of the 46 GF from group 4 have functionally
proven androgen resistance based on androgen-induced
APOD transcription in spite of the absence of anAR-CDS
mutation.
Molecular characterization of the AR-CDS
mutation negative but functionally androgen
resistant GF
Finallywewanted toknow ifmutationsdetectedwithin
the AR locus but outside the AR-CDS in individuals of
group4couldpotentiallyhave influencedARactivity.Out
of the 17 AR-CDS-mutation negative androgen resistant
GF, nine had one or more not annotated SNPs outside the
AR-CDS while eight had only previously annotated and
clinically unsuspicious SNPs in the region covered by our
NGS approach. The distribution of the not annotated
SNPs along the analyzed AR locus is shown in Figure 5a.
We speculated that a low APOD induction could be due
toa reducedARprotein expressionor stability in theseGF.
We checkedARprotein levels in all the 17GF cultures and
compared them to their appropriate control groups (scro-
tum and foreskin) (Figure 5b and c, Table 1). A lower AR
protein expression was seen in four GF of the AR-muta-
tionnegative androgen resistant group, indicating thatAR
protein expression was impaired in these cases. Two of
these four individuals had not annotated SNPs outside the
CDS (Table 1). In conclusion, we show that reduced AR
protein expression or stability can explain a reduced
APOD induction in about one fourth of the analyzed
cases.
Discussion
Functional assays for AR activity in
GF have been described before (16).
Lacking a target gene for the AR,
however, they were dependent on
the transfection of exogenous re-
porter constructs in order tomonitor
endogenous AR-activity. We here
provide theAPOD-assay as a tool for
the functional characterization of
cellular AR function in GF derived
from DSD patients. We validate its
diagnostic suitability in a very large
cohort using male controls, various
molecular well-defined DSD pa-
tients other than AIS, as well as sev-
eral genetically proven classical AIS
individuals. The resulting diagnostic
cutoffs not only helped to exclude
the diagnosis of AIS in many cases
but also lead to the identification of an androgen resistant
but AR-CDS-negative new class of AIS which we suggest
to call AIS type II. This is not only a significant addition to
the current classification of 46,XY-DSDs but also a start-
ing point for a better understanding of AR signaling, in-
cluding the identification of new AR cofactors in future
clinical and molecular DSD studies.
While the APOD-assay separates classical AIS from
male controls with high sensitivity and specificity, the sep-
arationwas slightly less specific when comparing classical
AIS from defined DSD diagnoses other than AIS. In fact,
one individual with documented 5RD-deficiency
(group2) showed reduced AR activity in the APOD-assay.
A possible explanation could be that this individual has a
defect both in DHT synthesis and in androgen action. An
additional 5RD-deficiency may also be responsible for
the CAIS phenotype of an individual carrying a
p.Tyr781Asp mutation in the ligand binding domain of
the AR, as biochemical data indicate reduced 5RD-ac-
tivity in GF of this patient ( (17); ID:C31). Both the resid-
ual APOD induction shown in this paper and previously
published DHT binding and dissociation studies (17) in-
dicate only an incomplete loss of AR-function in this in-
dividual in spite of a complete female phenotype.
Also, the APOD-assay did not distinguish between
PAIS and CAIS in all cases. This overlap may be affected
by specific functional and molecular conditions in some
individual GF cultures. In GF from a CAIS individual car-
rying a p.Val867Met mutation in the AR-ligand binding
domain we observed residual APOD induction with 10
nMDHT despite a clinical CAIS. Interestingly, noAPOD
A
B C
Figure 5. Analysis of AR-CDS mutation-negative but functionally androgen insensitive GF. a)
Distribution of potentially damaging mutations in the sequenced region outside the AR-CDS b)
AR protein expression in male scrotum-derived controls and AR-CDS mutation negative but
functionally androgen insensitive labioscrotal GF c) AR protein expression in male foreskin-
derived controls and AR-CDS mutation negative but functionally androgen insensitive GF.
Included are means and standard deviations.
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induction was measured when using 1 nMDHT, suggest-
ing that the CAIS phenotype might have originated from
low local genital DHT concentrations during embryogen-
esis. This observation is supported by the literature asso-
ciating this mutationwith different AIS phenotypes, rang-
ing from CAIS through PAIS to MAIS (14). Another
phenomenon with functional relevance for the APOD-as-
say may be the presence of somatic mosaicismwhich is an
apparently frequent condition in AIS due to the high new
mutation rate (18, 19). In the PAIS subgroupwithin group
3 of our study one cell line contained a p.Leu174stop mo-
saic (20) present in 94% of the cultured GF according to
the NGS reads. No APOD induction could be detected,
well in linewith the high percentage of themutation in this
PAIS cell culture. Hence, while the APOD-assay correctly
identified AIS in this situation, somatic mosaicism may
influence the detected level of functional impairment
which may be in contrast to the clinical phenotype. We
have previously described this phenomenon of discrep-
ancybetweenmolecular studies and the clinical phenotype
inmosaicAIS, using other functional approaches (19, 21).
Ultimately, due to limited information regarding the exact
AIS-grades of the genital phenotypes in our DSD-GF-bio-
bank (eg, according to Quigley et al (22) or to Ahmed et
al (23)) we cannot provide a meaningful AIS-grade/
APOD-assay correlation to date. The APOD-assay is
therefore currently not a statistically proven tool for as-
sessing the quantitative extent of androgen resistance in a
given individual with DSD.
By analyzing sequencing data of the AR locus outside
the AR-CDS we could detect so far not annotated SNPs
within potentially regulatory regions. Some of these SNPs
arepotential candidates for influencingARactivity as they
are paralleled by reduced AR protein expression in the
corresponding GF cultures which could explain the lower
AR activity in the AIS type II individuals. Interestingly, we
previously detected a mutation in the 5UTR of the AR in
an individual having CAIS and experimentally showed
that this mutation is sufficient to strongly reduce AR pro-
tein levels and AR activity (24). This underlines the im-
portance of detection of potential mutations outside the
AR-CDS. Another promising group of factors outside the
AR gene region that might contribute to AIS type II are
AR-cofactors which are needed for proper AR activity (5,
6). Numerous cofactors of the AR have been described in
prostate cancer (25) but a coregulator that exclusively reg-
Table 1. List of AR-CDS mutation negative but functionally androgen insensitive GF
GF
origin of
biopsy
SNP (chromosome
reference>alternate)
APOD
induction
AR protein
expression Encode regulation (hg19)
GF-89 S nothing 1.26 0.00
GF-107 S chrX:66 912 572 GA 2.27 0.19 strong enhancer in HSMM
GF-104 S nothing 1.30 0.38
GF-105 S nothing 1.64 0.40
GF-90 S chrX:66 839 548 GA 2.26 0.68 strong enhancer in HUVEC
GF-109 S chrX:66 811 878 TC 1.64 0.78 polycomb repressed in
GM12878, K562, H1-hESC,
HELA, HUVEC, HepG2
GF-86 S nothing 2.25 0.95
GF-118 S chrX:66 922 786 AG 1.25 1.05 /
GF-164 F chrX:66 877 648 GA 1.52 0.13 polycomb repressed in
GM12878, K562, H1-hESC,
HELA, HUVEC, HepG2
GF-158 F nothing 1.76 0.48
GF-162 F chrX:66 864 354 AG; chrX:
66 860 551 CA
2.08 0.82 polycomb repressed in
GM12878, K562, H1-hESC,
HELA, HUVEC, HepG2
GF-160 F chrX:66 795 584 AG; chrX:
66 817 032 3bp del
2.11 0.88 polycomb repressed in
GM12878, K562, H1-hESC,
HELA, HUVEC, HepG2; Pol2
associated transcription in H1-
hESC
GF-159 F chrX:66 933 579 GC 1.95 0.90 transcription in HUVEC
GF-168 F nothing 2.17 1.00
GF-157 F nothing 2.23 1.09
GF-163 F chrX:66 833 033 AG 2.22 1.14 strong enhancer in HUVEC and
HSMM
GF-166 F nothing 1.11 1.61
HSMM (Human Skeletal Muscle Cells and Myoblasts); GM12878 (B-lymphocyte); K562 (leukemia cell line); H1-hESC (H1 human embryonic stem
cells); HELA (cervical carcinoma cells); HUVEC (Human Umbilical Vein Endothelial Cells); HepG2 (liver hepatocellular carcinoma cells).
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ulates the AR has not been described so far. Since the AR
gene was cloned in 1988 (26, 27), only one single case of
disrupted AR activation through a coactivator defect has
been reported in a CAIS individual (28), but this coacti-
vator has never been identified. No further case has since
been described.
We do not yet know whether the AIS type II cohort
identified in this study has a monogenic origin or whether
multiple aberrant genes may contribute to this entity. Ex-
ome sequencing of the AR-CDS-negative AIS type II co-
hort in comparison with the other three cohorts of this
study is one of the next important experimental steps
planned. Furthermore, we cannot exclude that mild func-
tional AIS type II may play a role as secondary modifier
contributing to a DSD phenotype, even in certain molec-
ular-defined DSDs and in unknown DSDs. This is sup-
ported by previous reports documenting the existence of
more than one compromisedmolecular factor in the same
DSD individual (29–31). According to Cox K. et al (32)
associated conditions occur in about a quarter of analyzed
DSD cases. Looking specifically at cases with suspected
androgen insensitivity syndrome in 11% anomalies were
reported. In our AR-CDS-negative AIS type II cohort we
found documented minor syndromic signs in four out of
46 cases, hence 9%. In addition, prenatal conditions lead-
ing to low birth weight (LBW) may have programming
effects on androgen responsiveness of genital cells, since a
correlation of a LBW and a ´PAIS-like´ phenotype in in-
dividuals without an AR-gene mutation has been de-
scribed before (33).
Currently, our data are based on retrospective analyses
of fibroblasts obtained from our DSD-biobank, but they
can, nevertheless, be of potential value for the clinical en-
docrinologist. Apart from being an explanation for the
phenotypic development of a DSD individual, reduced
APOD inductionmay be associatedwith a reduced future
AR sensitivity during puberty and may influence clinical
response to androgen treatment. Prospective data are
needed to correlate APOD expression with clinical out-
come parameters in affected individuals. Given the high
significance of the data provided in this manuscript, the
scientific community in DSD research should revisit the
clinical indication of a diagnostic genital skin biopsy in
specific unclear DSD cases.
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